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Abstract
Background: Sudomotor dysfunction is manifested clinically as abnormal sweating leading to dryness of feet skin
and increased risk of foot ulceration. The aim of this study was to test the performance of foot electrochemical skin
conductance (ESC) to detect diabetic peripheral neuropathy and the risk of foot ulceration against traditional
methods in Saudi patients with diabetes mellitus.
Methods: This cross-sectional study was conducted on 296 Saudi patients with diabetes mellitus. Painful neuropathic
symptoms were evaluated using the neuropathy symptom score (NSS). The risk of foot ulceration and diabetic
peripheral neuropathy were determined using the neuropathy disability score (NDS). Vibration perception threshold
(VPT) was assessed using neurothesiometer. Neurophysiological assessment of the right and left sural, peroneal and
tibial nerves was performed in 222 participants. Diabetic peripheral neuropathy was defined according to the definition
of the American Academy of Neurology. ESC was measured with Sudoscan.
Results: Feet-ESC decreased as the scores of sensory and motor function tests increased. Feet-ESC decreased as the
NSS, NDS and severity of diabetic peripheral neuropathy increased. Sensitivity of feet-ESC < 50μS to detect diabetic
peripheral neuropathy assessed by VPT≥ 25 V, NDS≥ 3, NDS≥ 6 was 90.1, 61 and 63.8 % respectively and specificity
77, 85 and 81.9 % respectively. Sensitivity of feet-ESC < 70μS to detect diabetic peripheral neuropathy assessed by
VPT≥ 25 V, NDS≥ 3, NDS≥ 6 was 100, 80.6 and 80.9 % respectively. Sensitivity and specificity of feet-ESC < 70μS to
detect confirmed-diabetic peripheral neuropathy were 67.5 and 58.9 % respectively.
Conclusion: Sudoscan a simple and objective tool can be used to detect diabetic peripheral neuropathy and the risk
of foot ulceration among patients with diabetes mellitus. Prospective studies to confirm our results are warranted.
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Background
Diabetic autonomic neuropathy is a disorder of the
autonomic nervous system affecting the cardiovascular,
gastrointestinal and urogenital systems and sudomotor
function in the setting of diabetes mellitus (DM) and
metabolic derangements of pre-diabetes after exclusion
of other causes [1].
In the context of diabetic peripheral neuropathy (DPN)
sudomotor dysfunction (SMD) can occur in two pheno-
types: either as one component of a generalized DPN, or
concurrently in distal small fiber sensory polyneuropathy
(SFSN) [2].
Sudomotor C-fibers are postganglionic, unmyelinated,
cholinergic, sympathetic nerves that innervate sweat
glands, and SMD is manifested clinically as abnormal
sweating leading to skin dryness. Dryness of foot skin as
a result of SMD is associated increased risk of foot ul-
ceration (FU) [3].
Prevention of FU in patients with DM continues to
represent an important issue, as the steady rise in the
prevalence of DM is leading to a persistent burden of
DM-related complications including lower limb amputa-
tions [4]. Approximately 84 % of non-traumatic amputa-
tions occurring in diabetes are preceded by FU [5].
While peripheral artery disease accounts for an in-
creased risk of FU in only 35 % of cases, DPN contrib-
utes to 78 % of the risk of FU, and together with foot
deformity and repetitive trauma forms the clinical triad
that leads to FU [5, 6].
As such, every effort is needed to detect DPN includ-
ing SMD early in the course of the disease in order to
identify those patients in need of special care to minimize
the risk of FU and prevent limb loss. Utilization of tests to
assess SMD in daily practice has been limited, as the
known standardized methods to do so are either invasive,
complex, time-consuming or require specialized equip-
ment and training [2].
Recent introduction of sudorimetry technology using
Sudoscan which measures electrochemical skin conduct-
ance (ESC) of the hands and feet based on reverse ionto-
phoresis and chronoamperometry has allowed rapid,
noninvasive, robust, accurate assessment of sudomotor
and small nerve fiber function [7]. ESC measurement re-
quires little technical training and no calculations and
can easily be integrated into daily practice.
Over the past three decades the prevalence of DM in
Saudi Arabia has increased approximately 10-fold [8]. As
DPN is the earliest and most common long term com-
plication of DM [5, 9], it is imperative to validate and
utilize novel screening and diagnostic methods [10], in
particular those that are simple, non-invasive, easy to
use at a point of care and that have the potential to over-
come barriers to screening for and detecting DPN in-
cluding SMD.
The aim of our study was to test the performance of
feet-ESC to detect DPN and the risk of FU against trad-
itional methods among Saudi patients with DM.
Methods
A cross-sectional observational study was conducted at
the diabetes care center, King Salman hospital in Riyadh,
Kingdom of Saudi Arabia between January and May 2012.
Informed consent was obtained from all participants.
Study population
Participants in the study consisted of two hundred ninety
six Saudi Arabian patients with DM referred for the first
time from primary care health centers for general diabetes
care. Exclusion criteria included patients younger than 18-
or older than 65 years of age; patients with secondary
causes of DPN, peripheral vascular disease or active foot
ulcer; or patients taking drugs that affect autonomic func-
tion testing such as β-blockers or atropine.
Clinical assessment
Physical examination including detailed feet assessment
was conducted by physicians as described by Boulton
AJ et al [11]. Characteristics of the appearance of the
feet were documented for the presence of dryness, fis-
sures, calluses and deformities.
Painful neuropathic symptoms (PNS) were evaluated
using the neuropathy symptom score (NSS) [12]. Symp-
toms were considered positive if NSS ≥ 5. Diabetic per-
ipheral neuropathy and the risk of FU were determined
using the neuropathy disability score (NDS). DPN was
present if NDS ≥ 3. Risk of FU was present if NDS ≥ 6
[12]. Severity of DPN was graded according to NDS
scores: None (0–2), Mild (3–5), Moderate (6–8), Severe
(9–10) [12]. Scores for NDS were derived from ankle re-
flex testing using a reflex hammer, vibration sensation
using a 128Hz tuning fork, pain sensitivity using the
neurotip and differences in temperature sensation using
warm cold rod. Pressure sensation was tested using a
10-g monofilament as described by Boulton AJ et al [11].
Quantitative sensory testing (QST) to determine vibra-
tion perception threshold (VPT) was performed using a
neurothesiometer on both halluces. Complete blood count
was performed using (Hematology Analyzer, Sysmex XT
2000i), HbA1c was performed using (Dimension Xpand™
Rxl max, Hemoglobin A1c), the method has been certified
for precision and accuracy by the National Glycohemoglo-
bin Standardization Program (NGSP) ensuring clinical re-
sults consistent with the findings of the Diabetes Control
and Complication Trial (DCCT). Blood chemistry was
performed in the morning after 12 h fasting using
(Chemistry Analyzer, Dimension Xpand™ Rxl max).
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Neurophysiological assessment
Nerve conduction study was performed in 222 partici-
pants using Nicolet Viking Quest, VIASYS Healthcare
Inc Neurocare Group USA. Right and left sural sensory
amplitude and conduction velocity and peroneal and tib-
ial motor amplitudes, latencies and conduction velocities
were measured. Results were compared to age specific
normal values to determine nerve conduction study ab-
normality. Participants were then classified as having
normal, subclinical (ie nerve conduction abnormality
but without symptoms or signs of DPN) or confirmed
DPN as described by Tesfaye S et al 2010 [1]. Confirmed
DPN was present if the participant had at least one
symptom or sign of DPN and one or more abnormal
nerve conduction test in both sural (sensory) and
peroneal or tibial (motor) nerves in accordance with the
case definition of DPN described by the American
Academy of Neurology [13].
Sudomotor assessment
Measurement of ESC of both hands and feet was per-
formed using Sudoscan. Participants placed their hands
and feet on two sets of large-stainless-steel electrodes
which were connected to a computer for recording and
data management. Electrochemical skin conductance is
the ratio of the current measured over the constant
power applied expressed in micro-Simens (μS) for the
hands and feet (right and left sides). Through reverse
iontophoresis, the device generates voltage to the cath-
ode and a current (intensity of around 0.2 mA) occur
between the anode and cathode proportional to sweat
chloride concentration. At low voltage (<10 V) the
stratum corneum is electrically insulating and only
sweat gland ducts are conductive. Sudomotor dysfunc-
tion is absent if measured hands-ESC is ≥60μS or feet-
ESC ≥ 70μS. Moderate SMD is present if measured
hands-ESC is ≥40 but < 60 μS or feet-ESC is ≥50 but <
70 μS. Severe SMD is present if measured hands-ESC
is <40μS or feet-ESC is <50μS. These thresholds have
been defined based on previous studies [14–16]. The
test lasts less than 3 min and is painless.
Statistical analysis
Data are presented as mean ± SD or percentages. Pearson’s
correlation coefficient was used to evaluate the relation-
ship between feet-ESC and clinical and biochemical vari-
ables as well as bedside-tests, QST, and neurophysiologic
testing to detect DPN. Variances between variables were
calculated using an independent T test. For all the tests a
P value of 0.05 or less was used for statistical significance.
Sensitivity and specificity for feet-ESC to detect DPN and
the risk of FU were calculated against the cutoff values of
VPT ≥ 25 V, NDS ≥ 3, confirmed-DPN for the presence of
DPN and NDS ≥ 6 for the presence of increased risk of FU
using Bland-Altman plots [12, 17, 18]. Receiver operating
characteristic (ROC) curves were constructed and area
under the curve (AUC) calculated. Statistical Package for
Social Sciences (SPSS) version 20 for windows was used
for statistical analysis.
Results
The mean age of the participants was 46.7 ± 11.2 years.
Type 2 DM (T2DM) was present in 91.9 % of the partic-
ipants and 8.1 % had type 1 DM. Male to female ratio
was 1.01. Duration of DM was 6.97 ± 7.1 years. Body
mass index was 30.9 ± 7.1 kg/m2. History of FU was
present in (11) 3.7 % of the participants. Hypertension
and dyslipidemia were present in (109) 36.8 % and (144)
48.6 % of the participants respectively and 80.1 % led a
sedentary life-style. Diabetic retinopathy was present in
(16) 5.4 % of the participants.
Painful neuropathic symptoms (PNS) were present in
(154) 52 % of the participants and moderate PNS as de-
fined by NSS ≥ 5 were present in 53 (18.2 %). DPN as
defined by NDS ≥ 3 was present in (67) 22.6 % of the
participants and 15.9 % had increased risk of FU as de-
fined by NDS ≥ 6. DPN of moderate severity was present
in 35 (11.8 %) of the participants.
Quantitative sudorimetry using hands and feet-ESC
was performed in all patients. As hands-ESC correlated
significantly with feet-ESC (Table 1), we used only feet-
ESC to analyze the relationship of sudorimetry with the
other variables. Among all participants, 137 (46.3 %) had
no SMD: feet-ESC ≥ 70 μS, 84 (28.4 %) had moderate
SMD: feet-ESC < 70- ≥ 50 μS and 75 (25.3 %) had severe
SMD: feet-ESC < 50 μS.
There was a significant negative correlation between
feet-ESC and age, duration of DM and a past history of
FU (-0.234 p < 0 .0001), (-0.301 p < 0 .003), and (-0.366
p < 0 .0001) respectively. Feet-ESC decreased in the pres-
ence of diabetic retinopathy (-0.170 p < 0 .003) and ele-
vation of systolic blood pressure (-0.129, p < 0 .036).
Feet-ESC also decreased with rising levels of serum cre-
atinine (-0.143, p < 0 .014) and uric acid (-0.162, p < 0
.008). Notably feet-ESC increased with increasing levels
of physical activity (0.171, p < 0 .0001). Analysis of the
relationship between feet-ESC and the levels of fasting
blood glucose (FBG) and HbA1c showed an insignificant
inverse relationship: (-0.026, p < 0.66), and (-0.062, p <
0.31) respectively. However there was a positive correl-
ation between both FBG and HbA1c and patients who
are in the category of severe SMD (feet-ESC < 50 μS) as
a group, (0.118, p < 0.044), (0.134, p < 0.029) respectively.
Table 1 presents trends in the correlation coefficients
between feet-ESC and tests of peripheral nerve function.
The values of feet-ESC decreased as the bedside sensory
and motor function tests and VPT assessed quantita-
tively by neurothesiometer increased. The values of feet-
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ESC also decreased with increasing scores of NSS,
NDS ≥ 3, and NDS ≥6 reflecting the presence of PNS,
DPN and the risk of foot ulceration (RFU). As the sever-
ity of DPN increased, the values of feet-ESC decreased.
ESC-feet decreased as the amplitude and conduction
velocity of the sensory and motor nerves decreased. Not-
ably there was a positive correlation between feet-ESC
and both pain sensation and differences in temperature
sensation.
Table 2 presents variances in the mean feet-ESC be-
tween participants with and without PNS, DPN, in-
creased risk of FU and confirmed DPN. There was a
significant decrease in feet-ESC among participants with
DPN compared with those without DPN. Further ana-
lysis showed significantly lower values of feet-ESC in pa-
tients with confirmed DPN as compared with
participants with subclinical DPN (54.7 ± 24.8 vs 70.2 ±
14.14 μS; P < 0.0001).
Table 3 demonstrates the performance of severe SMD
(feet-ESC <50μS) to detect DPN and the risk of foot ul-
ceration, against the traditional tests, in particular:
VPT ≥ 25 V, NDS ≥ 3 and NDS ≥ 6. Feet-ESC < 50 μS was
sensitive and specific in detecting DPN and the risk of
FU among participants. Similarly, feet-ECS <70μS was
highly sensitive but less specific in detecting DPN
assessed by VPT, NDS and confirmed DPN (defined by
the criteria of the American Academy of Neurology
2005 [13]) with a notable high positive predictive (PPV)
value for confirmed DPN. Figure 1 demonstrates the
ROC curve of feet-ESC to reflect DPN assessed by
VPT ≥ 25 V.
Discussion
We demonstrated that in Saudi patients with DM, severe
SMD as defined by a feet-ESC threshold below 50 μS
was sensitive and highly specific in detecting DPN
assessed by VPT and NDS. Feet-ESC < 50 μS was sensi-
tive and specific in detecting the risk of FU as well.
Furthermore feet-ESC threshold below 70μS, showed
moderate sensitivity to detect confirmed-DPN assessed
by neurophysiological studies and classified according to
the American Academy of Neurology 2005 criteria. In
an earlier publication Casellini C et al showed that feet-
ESC exhibited high sensitivity and specificity to detect
DPN evaluated by the Neuropathy Impairment Score-
Lower Legs (NIS-LL) [14]. In patients with type 1 DM,
Selvarajah D et al have demonstrated that feet-ESC was
sensitive and specific to identify confirmed-DPN classi-
fied according to AAN criteria [19].
Additionally we showed that feet-ESC was able to dif-
ferentiate between participants with and without DPN
assessed by NDS and neurophysiological testing. Our
Table 1 Pearson’s correlation coefficient of feet-ESC with tests
of peripheral nerve function among the participants
No Tests CC P
1 ESC-hands 0.592 <0 .0001
2 Pain sensitivity 0.406 <0 .0001
3 Differences in temperature perception 0.304 <0 .0001
4 Achilles Reflex -0.405 <0 .0001
5 Vibration perception by 128Hz tuning fork -0.391 <0 .0001
7 Pressure perception by 10 g-MF -0.300 <0 .0001
8 QST by neurothesiometer:VPT≥ 25 V -0.383 <0 .0001
9 Sural nerve amplitude 0.163 <0.014
10 Sural nerve velocity 0.249 <0.0001
11 Peroneal nerve amplitude 0.184 <0.006
12 Peroneal nerve velocity 0.278 <0.0001
13 Painful DPN by NSS ≥ 5 -0.230 <0 .0001
14 DPN by NDS≥ 3 -0.469 <0 .0001
15 Risk of foot ulcer by NDS ≥ 6 -0.398 <0 .0001
16 Severity of DPN by NDS ≥ 3 -0.442 <0 .0001
DPN diabetic peripheral neuropathy. ESC electrochemical skin conductance.
NSS Neuropathy symptom score. NDS neuropathy disability score. QST
quantitative sensory testing. VPT vibration perception threshold. 10-g MF 10
gram monofilament. CC correlation coefficient
Table 2 Variances in feet-ESC between participants without or
with painful neuropathic symptoms, diabetic peripheral
neuropathy, RFU, and confirmed neuropathy
NSS≥ 5 NDS ≥ 3 NDS≥ 6 Confirmed-DPN
No 67.1 ± 18.4 μS 67.4 ± 16.9 μS 65.6 ± 18.8 μS 67.6 ± 16.9 μS
Yes 57.1 ± 23.7 μS 42.9 ± 26.1 μS 41.9 ± 25.9 μS 53.7 ± 24.7 μS
P <0.0001 <0.0001 <0.0001 <0.0001
DPN diabetic peripheral neuropathy, NSS Neuropathy symptom score. NDS
neuropathy disability score. RFU risk of foot ulceration
Table 3 Performance of feet-ESC to detect diabetic peripheral
neuropathy and the RFU against traditional tests
Feet-ESC < 50μS
Sensitivity Specificity AUC PPV NPV +LH -LH
DPN:VPT≥ 25v 90.1 77 0.841 13 99 3.98 0.12
DPN:NDS≥ 3 61.2 85.2 0.732 54 85 4.12 0.46
RFU:NDS≥ 6 63.8 81.9 0.729 40 92 3.53 0.44
Confirmed-DPN 38.4 91 0.648 85.7 52 4.3 0.67
Feet-ESC <70μS
DPN:VPT≥ 25v 100 46 0.732 6.7 100 1.86 0
DPN:NDS≥ 3 80.6 51 0.663 32.5 90 1.66 0.38
RFU:NDS≥ 6 80.9 49 0.651 23 93 1.59 0.39
Confirmed-DPN 67.2 58.9 0.63 93 56 1.6 0.56
DPN diabetic peripheral neuropathy. RFU risk of foot ulceration. ESC
electrochemical skin conductance. VPT vibration perception threshold. NDS
neuropathy disability score. AUC area under the curve. PPV positive predictive
value. NPV negative predictive value. +LH positive likelihood. –LH
negative likelihood
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results are in agreement with results reported in other
studies. [14, 19, 20] These observations indicate that
sudorimetry using feet-ESC relates significantly to tests
of sensory and motor nerve function that are used to de-
tect large fiber-sensory polyneuropathy (LFSN).
On the other hand we have shown that 53.7 % of the
participants had either moderate or severe SMD
assessed by feet-ESC. Feet-ESC positively correlated with
tests to detect pain sensitivity and differences in
temperature sensation, both of which are bedside tests,
used to assess small fiber nerve function. Although as-
sessment of symptoms and even quantitative sensory
tests for cold, warm and pain sensitivity lack precision in
detecting small fiber nerve function [6] Smith et al have
shown similar performance of feet-ESC compared to
intraepidermal nerve fiber density (IENFD) obtained
from skin biopsy that is considered the gold standard for
diagnosing small fiber sensory neuropathy (SFSN) [15].
Together these results do not imply that ESC identifies
all forms of DPN, but rather reflect its ability to detect
the involvement of small C-fiber nerve dysfunction in a
generalized DPN in addition to the concurrent occur-
rence of autonomic and somatic C-fiber dysfunction in
SFSN. This fact confers a potential role for ESC to
screen for both LFSN and SFSN in addition to SMD.
Being simple, non-invasive, quick, and objective and re-
quiring no training or special patient preparation quali-
fies ESC as a suitable measurement tool to screen for
DPN in busy diabetes clinics.
The strength of our study lies in the fact that we per-
formed neurophysiological tests on a large number of par-
ticipants (222) to define DPN in addition to bedside tests.
We also demonstrated that in Saudi patients with DM,
quantitative sudorimetry using feet-ESC was related not
only to traditional tests for identifying DPN but also to
the factors that are associated with increased risk for de-
veloping DPN. Feet-ESC decreased with increasing age,
duration of DM, systolic blood pressure and a past his-
tory of FU. Earlier Yajnik et al demonstrated a positive
correlation of feet-ESC with age and duration of DM
[20]. A decrease in the feet-ESC levels was observed with
rising levels of serum uric acid. This is in agreement with
results reported by Papanas N et al who demonstrated
that increased levels of uric acid represents a risk factor
for DPN in general and SMD in particular [21, 22].
Analysis of the relationship between indices of gly-
cemic control and feet-ESC showed a significant posi-
tive correlation between both fasting blood glucose
Fig. 1 Feet-ESC receiver-operating characteristic curve ROC to reflect diabetic peripheral neuropathy assessed by VPT≥ 25 V. Area under the
curve = 0.918, P < 0.0001
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levels, HbA1c and feet-ESC threshold of severe SMD
(feet-ESC < 50 μS) that probably represents established
SMD. Results are in agreement with findings by Yajnik
et al, [20] and imply that uncontrolled DM increases
the risk of developing SMD. Decreased feet-ESC was
also associated with the presence of diabetic retinop-
athy and increasing levels of serum creatinine. Gin et al
also demonstrated an inverse relationship between ESC
and diabetic retinopathy (-0.42, p < 0.0001) [23]. The re-
lationship demonstrated in our study between indices of
blood glucose control and severe SMD ie (feet-ESC < 50
μS), the presence of diabetic retinopathy and increasing
levels of creatinine (the three of which represent indica-
tors of diabetic microvascular complications) is in agree-
ment with the results of the landmark studies that have
shown a direct effect of glycemic control on the develop-
ment of diabetic microvascular complications including
DPN that encompasses SMD as well [24, 25]. It is worth
mentioning that several recent studies have suggested
utilization of a risk score based on ESC as a tool to
screen for chronic kidney disease and microvascular
complications [16, 26, 27].
An important finding of the study is the relationship
between feet-ESC and the level of physical activity among
the participants. Participants with a sedentary life-style
were at increased risk of SMD reflected by decreased feet-
ESC. This result emphasizes the role of PA in protecting
sudomotor small C-fiber nerves and is in agreement with
results reported by Raisanen A et al who demonstrated a
significant increase in estimated VO2max and hands and
feet-ESC observed after lifestyle intervention [28].
We did not compare sudorimetry using ESC with
other traditional tests to detect autonomic dysfunction.
This might be considered a weakness of our study; how-
ever others have shown that ESC significantly correlated
with the quantitative autonomic testing and with the
quantitative sudomotor axon reflex testing [14, 15].
Our study has demonstrated that more than half of
the studied Saudi patients with DM newly referred to a
specialized diabetes center had SMD assessed quantita-
tively using ESC and could thus be at risk of developing
FU. In this regard it is worth mentioning that a recent
cohort study has demonstrated that the prevalence of
diabetic foot complications among Saudi Arabian pa-
tients with DM is 3.3 %, and is within the estimated
international range [29]. This burden is expected to
grow as the prevalence of DM continues to rise in Saudi
Arabia [8]. Simplicity and reliability are therefore prereq-
uisites for a screening method to identify patients at risk
of FU, to be widely utilized as the prevalence of DM
continues to rise. The study showed that measuring ESC
is a simple, noninvasive, reliable, quantitative test that
can be introduced at a point of care to screen for SMD,
DPN and the risk of FU. Utilization of ESC will simplify
screening for DPN to identify patients at risk who are in
need of special care to prevent limb loss. Further studies
are warranted to support the results and prospective
studies should explore the potential of ESC to predict
the development of FU and test the effectiveness of in-
terventions to prevent SMD and FU.
Conclusion
Our study demonstrated that measuring feet-ESC is a
simple, noninvasive method with sufficient sensitivity
and specificity to identify patients with DM who are at
risk of FU.
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